FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to therapy and endocrinology, and is applicable to prevent severe symptomatic hypoglycaemia related to the blood glucose concentration of less than 50 mg/dl in type 2 diabetes mellitus. That is ensured by administering desPro36Exendin-4(1-39)-Lys6-NH2 (Lixisenatide) and/or its pharmaceutically acceptable salt, and metformin and/or its pharmaceutically acceptable salt in an individual in need thereof; the individual to be treated has min. HbA1c 8%. What is also presented is a pharmaceutical combination and using the combination.
EFFECT: group of inventions provides controlling blood glucose and body weight over a period of time of 24 weeks in obese patients of 50 years or younger suffering type 2 diabetes mellitus.
19 cl, 5 dwg, 29 tbl
